1-12 of 12
Guangrong Zheng
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy of a Novel BCL-XL Degrader, DT2216, in Preclinical Models of Post-Myeloproliferative Neoplasm Secondary AML

Zhe Wang, Anna Skwarska, Gowri Poigailwar, Sovira Chaudhry, Alba Rodriguez-Meira, Pinpin Sui, Emmanuel Olivier, Yannan Jia, Cassandra L. Ramage, Guangrong Zheng, Alexandra Schurer, Kira Gritsman, Eirini Papapetrou, Kapil N. Bhalla, Daohong Zhou, Adam J Mead, Raajit Rampal, Jeffrey W Tyner, Hussein A. Abbas, Naveen Pemmaraju, Qi Zhang Tatarata, Marina Konopleva
Journal: Blood
Blood (2024) 144 (Supplement 1): 2749.
https://doi.org/10.1182/blood-2024-194031
Published: 2024
Journal Articles

Protein Degrader WH25244 Eliminates Venetoclax Resistance Factors: Mutant or Hyperphosphorylated BCL2, and BCL-XL

Daisy Y. Diaz Rohena, Andrew D. Mitchell, Jing Wang, Stephanie Chamberlain, Chaomei Liu, John R. Sanchez, II, Charmelle D. Williams, Trisha K. Wathan, Bailey Slawin, Kevin Bowman, Yaxia Yuan, Peiyi Zhang, Wanyi Hu, Guangrong Zheng, William G. Wierda, Nitin Jain, Matthew S. Davids, Daohong Zhou, Jennifer A. Woyach, Deepa Sampath
Journal: Blood
Blood (2024) 144 (Supplement 1): 2786.
https://doi.org/10.1182/blood-2024-208159
Published: 2024
Journal Articles

Targeting BCL-XL with a Novel VHL-Based BCL-XL Degrader DT-2216 in Pre-Clinical JAK2 -Mutant AML Post-MPN Models

Zhe WANG, Qi Zhang, Anna Skwarska, Cassandra L. Ramage, Guangrong Zheng, Kira Gritsman, Kapil N. Bhalla, Naveen Pemmaraju, Daohong Zhou, Jeffrey W Tyner, Marina Y. Konopleva
Journal: Blood
Blood (2023) 142 (Supplement 1): 4154.
https://doi.org/10.1182/blood-2023-178813
Published: 2023
Journal Articles

Enriched Signalling Pathways in Venetoclax-Relapsed Chronic Lymphocytic Leukemia (CLL) Cells and Targeting Using a Protac-Based Bcl-2/Bcl-Xl Degrader

Daisy Diaz Rohena, Arnau Peris Cuesta, Bailey Slawin, Janani Ravikrishnan, Chaomei Liu, Charmelle Williams, Wanyi Hu, Peiyi Zhang, Philip Thompson, William G. Wierda, Nitin Jain, Sachet Shukla, Guangrong Zheng, Daohong Zhou, Jennifer A. Woyach, Deepa Sampath
Journal: Blood
Blood (2023) 142 (Supplement 1): 4195.
https://doi.org/10.1182/blood-2023-188250
Published: 2023
Journal Articles

Study of the Dynamics and Diversity of Hematopoietic Stem Cells during Aging and Senolytic Drug Treatment Using Single Cell Transcriptomics

Bowen Yan, Guangrong Zheng, Daohong Zhou, Olga A Guryanova
Journal: Blood
Blood (2022) 140 (Supplement 1): 5760–5761.
https://doi.org/10.1182/blood-2022-170033
Published: 2022
Journal Articles

Dual BCL-XL/2 Protac 753B Not Only Potently Induces Apoptosis in Venetoclax-Resistant Primary AML Cells but Also Effectively Eliminates Chemotherapy-Induced Senescent AML Cells

Yannan Jia, Lina Han, Cassandra L Ramage, Connie C. Weng, Lei Yang, Simona Colla, Helen Ma, Weiguo Zhang, Michael Andreeff, Naval Daver, Nitin Jain, Naveen Pemmaraju, Kapil N. Bhalla, Satu Mustjoki, Peiyi Zhang, Guangrong Zheng, Daohong Zhou, Qi Zhang, Marina Konopleva
Journal: Blood
Blood (2022) 140 (Supplement 1): 3347–3349.
https://doi.org/10.1182/blood-2022-164541
Published: 2022
Journal Articles

Targeting Venetoclax Resistant CLL Using a Protac-Based BCL-2/BCL-XL Degrader

Daisy Diaz Rohena, Bailey Slawin, Janani Ravikrishnan, Chaomei Liu, Wanyi Hu, Peiyi Zhang, Philip A. Thompson, William G. Wierda, Nitin Jain, Guangrong Zheng, Daohong Zhou, Jennifer A. Woyach, Deepa Sampath
Journal: Blood
Blood (2022) 140 (Supplement 1): 497–498.
https://doi.org/10.1182/blood-2022-168345
Published: 2022
Journal Articles

Targeting Venetoclax-Resistant CLL By Bcl-XL Degradation

Daisy Diaz Rohena, Janani Ravikrishnan, Chaomei Liu, Guangrong Zheng, Daohong Zhou, Peiyi Zhang, William G. Wierda, Nitin Jain, Jennifer A. Woyach, Deepa Sampath
Journal: Blood
Blood (2021) 138 (Supplement 1): 2252.
https://doi.org/10.1182/blood-2021-151982
Published: 2021
Journal Articles

Targeting BCL-XL and BCL-2 By Protac 753B Effectively Eliminates AML Cells and Enhances Efficacy of Chemotherapy By Targeting Senescent Cells

Yannan Jia, Qi Zhang, Weiguo Zhang, Michael Andreeff, Nitin Jain, Peiyi Zhang, Guangrong Zheng, Daohong Zhou, Marina Konopleva
Journal: Blood
Blood (2021) 138 (Supplement 1): 2230.
https://doi.org/10.1182/blood-2021-147535
Published: 2021
Journal Articles

DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), Is a Potent Anti T-Cell Lymphoma Agent That Does Not Induce Significant Thrombocytopenia

Yonghan He, MD, Raphael Koch, Vivekananda Budamagunta, Dongwen Lv, Sajid Khan, Xuan Zhang, Janet S Wiegand, Guangrong Zheng, David M. Weinstock, MD, Daohong Zhou
Journal: Blood
Blood (2019) 134 (Supplement_1): 303.
https://doi.org/10.1182/blood-2019-125820
Published: 2019
Journal Articles

Targeting BCL-XL By Protac DT2216 Effectively Eliminates Leukemia Cells in T-ALL Pre-Clinical Models

Qi Zhang, PhD, Sajid Khan, PhD, Xuan Zhang, Vinitha Mary Kuruvilla, MSc, Sanaz Ghotbaldini, Julia Wells, PhD, Natalia Baran, PhDMD, Tianyu Cai, PhD, Lina Han, PhD, Adolfo Ferrando, MD, PhD, Yong-Mi Kim, MD MPH, PhD, Guangrong Zheng, Daohong Zhou, Marina Y Konopleva, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3870.
https://doi.org/10.1182/blood-2019-124744
Published: 2019
Journal Articles

DT2216, a Synthetic Proteolytic Selectively Targeting Bcl-X L for Ubiquitination and Degradation in Tumor Cells but Not in Platelets, Is a Safer and More Potent Antitumor Agent Than Navitoclax

Sajid Khan, PhD, Xuan Zhang, BMBS, Dongwen Lv, PhD, Yonghan He, MD, Peiyi Zhang, MS, Xingui Liu, PhD, Dinesh Thummuri, PhD, Qi Zhang, PhD, Marina Y. Konopleva, MD PhD, Robert A. Hromas, MD, Guangrong Zheng, Daohong Zhou, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2698.
https://doi.org/10.1182/blood-2018-99-114762
Published: 2018